REGN

Regeneron Pharmaceuticals Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth 5/10
  • Value 2/10
Regeneron Pharmaceuticals sales and earnings growth
REGN Growth
Neutral
  • Revenue Y/Y 5.92%
  • EPS Y/Y 1.89%
  • FCF Y/Y 31.75%
Regeneron Pharmaceuticals gross and profit margin trends
REGN Profitability
Good
  • Gross margin 84.50%
  • EPS margin 29.60%
  • ROIC 5Y 15.82%
Regeneron Pharmaceuticals recent dividend growth
REGN Dividends
  • Dividend yield 0.53%
  • Growth 3Y 306.82%
  • Payout ratio 8%
Regeneron Pharmaceuticals net debt vs free cash flow
REGN Risk
Great
  • Debt / Equity 0.1
  • Debt / FCF 0.0
  • Interest coverage 108.4

Regeneron Pharmaceuticals stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

↗ More Biotechnology stocks